• Open Access

Comparative Analysis of Survivin Expression in Untreated and Relapsed Canine Lymphoma

Authors

  • R.B. Rebhun,

    1. Departments of Clinical Sciences, and Microbiology, Immunology and Pathology, Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO
    Search for more papers by this author
  • S.E. Lana,

    1. Departments of Clinical Sciences, and Microbiology, Immunology and Pathology, Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO
    Search for more papers by this author
  • E.J. Ehrhart,

    1. Departments of Clinical Sciences, and Microbiology, Immunology and Pathology, Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO
    Search for more papers by this author
  • J.B. Charles,

    1. Departments of Clinical Sciences, and Microbiology, Immunology and Pathology, Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO
    Search for more papers by this author
  • D.H. Thamm

    1. Departments of Clinical Sciences, and Microbiology, Immunology and Pathology, Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO
    Search for more papers by this author

Corresponding author: D.H. Thamm, VDM, Department of Clinical Sciences, Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523; e-mail: dthamm@colostate.edu.

Abstract

Background: Survivin, a member of the inhibitor of apoptosis protein family, has a dual role in tumor cell proliferative and antiapoptotic pathways. Survivin expression has been shown to be a negative prognostic factor in several cancers of humans, including B-cell non-Hodgkin's lymphoma.

Hypotheses: High survivin expression will be a negative prognostic factor in dogs with lymphoma (LSA) treated with chemotherapy. In addition, survivin expression will be upregulated in relapsed canine LSA when compared with patient-matched, pretreatment biopsies.

Animals: Thirty-one client-owned dogs with stage IIIa or IVa LSA.

Methods: Retrospective evaluation of survivin immunoreactivity was performed on pretreatment lymph node biopsies and patient-matched samples obtained from dogs at relapse after being treated with an abbreviated CHOP-based protocol.

Results: In this population of dogs presenting with stage IIIa or IVa B-cell LSA, those dogs that had high survivin immunoreactivity scores had a significantly (P < .01, hazard ratio = 0.30) shorter median disease-free interval than did dogs with low survivin immunoreactivity scores (171 days versus 321 days, respectively). Survivin immunoreactivity was not significantly different in relapsed canine LSA when compared with patient-matched, pretreatment biopsies.

Conclusions and Clinical Importance: Survivin expression is a negative prognostic factor that can predict early treatment failure of dogs that present with stage IIIa or IVa, B-cell LSA when treated with a CHOP-based protocol.

Ancillary